Eaton Vance Worldwide Health Sciences remains a solid source of global exposure to healthcare stocks rather than an outstanding one. The strategy retains its People and Process ratings of Average.
Eaton Vance Worldwide Health Sci A ETHSX
- NAV / 1-Day Return 13.53 / −0.44 %
- Total Assets 1.0 Bil
-
Adj. Expense Ratio
- Expense Ratio 1.140%
- Distribution Fee Level Below Average
- Share Class Type Front Load
- Category Health
- Investment Style Large Growth
- Min. Initial Investment 1,000
- Status Open
- TTM Yield 0.12%
- Turnover 21%
USD | NAV as of Apr 24, 2024 | 1-Day Return as of Apr 24, 2024, 10:14 PM GMT+0
Morningstar’s Analysis ETHSX
Will ETHSX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 52.7
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 9.42 | 96.8 Mil | Healthcare |
UnitedHealth Group Inc | 6.89 | 70.8 Mil | Healthcare |
Novo Nordisk A/S Class B | 6.57 | 67.5 Mil | Healthcare |
AbbVie Inc | 5.42 | 55.7 Mil | Healthcare |
Thermo Fisher Scientific Inc | 5.12 | 52.6 Mil | Healthcare |
AstraZeneca PLC | 4.32 | 44.4 Mil | Healthcare |
Danaher Corp | 3.97 | 40.8 Mil | Healthcare |
Intuitive Surgical Inc | 3.84 | 39.5 Mil | Healthcare |
Roche Holding AG | 3.61 | 37.1 Mil | Healthcare |
Johnson & Johnson | 3.54 | 36.4 Mil | Healthcare |